BetterLife Pharma Settles Debts with Share Issuance

BetterLife Pharma ( (TSE:BETR) ) has provided an update.

BetterLife Pharma has announced the issuance of nearly 15 million common shares to settle accounts payable and amounts due to directors and officers, totaling approximately $1.5 million. This move, which includes a significant settlement with company officers and directors, reflects BetterLife’s efforts to manage its financial obligations while continuing its focus on developing treatments for psychiatric and neurological disorders.

Spark’s Take on TSE:BETR Stock

According to Spark, TipRanks’ AI Analyst, TSE:BETR is a Underperform.

BetterLife Pharma is currently in a precarious financial position with no revenue, substantial losses, and a high leverage risk due to negative equity. Technical indicators show a lack of momentum, and the valuation is unattractive due to negative earnings. The overall outlook is negative, reflecting significant financial instability.

To see Spark’s full report on TSE:BETR stock, click here.

More about BetterLife Pharma

BetterLife Pharma Inc. is an emerging biotechnology company focused on developing and commercializing compounds for the treatment of neuro-psychiatric and neurological disorders. The company is working on BETR-001, a non-hallucinogenic neuroplastogen, and BETR-002, based on honokiol, for treating various disorders. Additionally, BetterLife owns a drug candidate for viral infections and is exploring strategic alternatives for its development.

Average Trading Volume: 62,948

Technical Sentiment Signal: Sell

Current Market Cap: C$11.66M

Find detailed analytics on BETR stock on TipRanks’ Stock Analysis page.